Trial Outcomes & Findings for Functional Electrical Stimulation for Footdrop in Hemiparesis (NCT NCT00148343)

NCT ID: NCT00148343

Last Updated: 2018-06-01

Results Overview

Lower limb motor impairment as measured by the lower limb portion of the Fugl-Meyer Assessment (FMA) which consists of 17 items, with a maximum possible score of 34 points, with lower scores indicating higher impairment. Each item was answered using a 3-point ordinal scale (0 = cannot perform, 1 = can partially perform, 2 = can fully perform).

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

110 participants

Primary outcome timeframe

Weeks 0, 12, 24, 36

Results posted on

2018-06-01

Participant Flow

Subjects screened over 5-yr study period: 469. Subjects completing informed consent and eligibility eval: 158. Subjects enrolled: 110. Last date of enrollment:10/27/2009. Final date subject study completion: 8/2/2010. All subject screening, enrollment, and study participation took place at an academic medical center.

Enrolled subjects (n=110) were stratified by presence or absence of dorsiflexion, based on clinical exam, prior to randomization into treatment and control groups. No enrolled subjects were excluded from the trial prior to assignment to groups.

Participant milestones

Participant milestones
Measure
Peroneal Nerve Stimulation (PNS)
The peroneal nerve stimulator used in this study was the Odstock Dropped-Foot Stimulator (ODFS).
Standard of Care (no Device or Ankle Foot Orthosis)
Conventional Standard of Care was defined as either 1) no device or 2) a custom molded hinged ankle foot orthosis (AFO). Standard of care intervention device was determined based on clinical indication.
Overall Study
STARTED
54
56
Overall Study
COMPLETED
39
45
Overall Study
NOT COMPLETED
15
11

Reasons for withdrawal

Reasons for withdrawal
Measure
Peroneal Nerve Stimulation (PNS)
The peroneal nerve stimulator used in this study was the Odstock Dropped-Foot Stimulator (ODFS).
Standard of Care (no Device or Ankle Foot Orthosis)
Conventional Standard of Care was defined as either 1) no device or 2) a custom molded hinged ankle foot orthosis (AFO). Standard of care intervention device was determined based on clinical indication.
Overall Study
Withdrawal by Subject
12
7
Overall Study
Physician Decision
3
4

Baseline Characteristics

Functional Electrical Stimulation for Footdrop in Hemiparesis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Peroneal Nerve Stimulation
n=54 Participants
Odstock Dropped Foot Stimulator
Standard of Care
n=56 Participants
No device or ankle foot orthosis
Total
n=110 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
47 Participants
n=99 Participants
51 Participants
n=107 Participants
98 Participants
n=206 Participants
Age, Categorical
>=65 years
7 Participants
n=99 Participants
5 Participants
n=107 Participants
12 Participants
n=206 Participants
Age, Continuous
52.8 years
STANDARD_DEVIATION 12.2 • n=99 Participants
53.2 years
STANDARD_DEVIATION 10.1 • n=107 Participants
53.0 years
STANDARD_DEVIATION 11.1 • n=206 Participants
Sex: Female, Male
Female
24 Participants
n=99 Participants
19 Participants
n=107 Participants
43 Participants
n=206 Participants
Sex: Female, Male
Male
30 Participants
n=99 Participants
37 Participants
n=107 Participants
67 Participants
n=206 Participants
Region of Enrollment
United States
54 participants
n=99 Participants
56 participants
n=107 Participants
110 participants
n=206 Participants

PRIMARY outcome

Timeframe: Weeks 0, 12, 24, 36

Population: For intent-to-treat analysis, all participants who were randomized and completed baseline assessments were included in the analysis

Lower limb motor impairment as measured by the lower limb portion of the Fugl-Meyer Assessment (FMA) which consists of 17 items, with a maximum possible score of 34 points, with lower scores indicating higher impairment. Each item was answered using a 3-point ordinal scale (0 = cannot perform, 1 = can partially perform, 2 = can fully perform).

Outcome measures

Outcome measures
Measure
Peroneal Nerve Stimulation
n=53 Participants
Odstock Dropped Foot Stimulator
Standard of Care
n=55 Participants
No device or ankle foot orthosis
Fugl-Meyer Motor Assessment (FMA)
Baseline
20.1 units on a scale
Standard Deviation 5.9
20.3 units on a scale
Standard Deviation 6.0
Fugl-Meyer Motor Assessment (FMA)
12- weeks
21.5 units on a scale
Standard Deviation 6.27
21.18 units on a scale
Standard Deviation 5.72
Fugl-Meyer Motor Assessment (FMA)
24- weeks
21.26 units on a scale
Standard Deviation 6.05
21.17 units on a scale
Standard Deviation 5.58
Fugl-Meyer Motor Assessment (FMA)
36 weeks
21.93 units on a scale
Standard Deviation 5.84
21.02 units on a scale
Standard Deviation 5.69

SECONDARY outcome

Timeframe: Weeks 0, 12, 24, 36

The number of steps taken by participants in one minute

Outcome measures

Outcome measures
Measure
Peroneal Nerve Stimulation
n=54 Participants
Odstock Dropped Foot Stimulator
Standard of Care
n=56 Participants
No device or ankle foot orthosis
Steps Per Minute
Baseline
65.0 Steps/Min
Standard Deviation 22
66.7 Steps/Min
Standard Deviation 22.7
Steps Per Minute
12-weeks
67.4 Steps/Min
Standard Deviation 21.5
72.6 Steps/Min
Standard Deviation 22.6
Steps Per Minute
24-weeks
69.3 Steps/Min
Standard Deviation 26.35
72.0 Steps/Min
Standard Deviation 23.16
Steps Per Minute
36-weeks
70.84 Steps/Min
Standard Deviation 26.83
73.74 Steps/Min
Standard Deviation 22.73

SECONDARY outcome

Timeframe: Weeks 0, 12, 24, 36

The mEFAP comprises 5 individually timed tasks performed over different environmental terrains. The subtasks include (1) a 5-meter walk on a hard floor; (2) a 5-meter walk on a carpeted surface; (3) rising from a chair, a 3-meter walk, and return to a seated position (the "timed up-and-go" test); (4) traversing a standardized obstacle course; and (5) ascending and descending 5 stairs. The mEFAP is performed with or without the use of an orthotic device or an AD. Manual assistance (MA) is provided as necessary. The subject can use rails when climbing the stairs. The 5 timed subscores are added to derive a total score in seconds.

Outcome measures

Outcome measures
Measure
Peroneal Nerve Stimulation
n=54 Participants
Odstock Dropped Foot Stimulator
Standard of Care
n=56 Participants
No device or ankle foot orthosis
Modified Emory Functional Ambulation Profile(mEFAP)
Baseline
121.54 seconds
Standard Deviation 86.59
118.39 seconds
Standard Deviation 74.10
Modified Emory Functional Ambulation Profile(mEFAP)
12- weeks
107.92 seconds
Standard Deviation 78.80
93.47 seconds
Standard Deviation 73.02
Modified Emory Functional Ambulation Profile(mEFAP)
24-weeks
110.81 seconds
Standard Deviation 81.89
97.25 seconds
Standard Deviation 71.4
Modified Emory Functional Ambulation Profile(mEFAP)
36-weeks
111.81 seconds
Standard Deviation 83.16
96.20 seconds
Standard Deviation 65.20

SECONDARY outcome

Timeframe: Weeks 0, 12, 24, 36

The Stroke Specific Quality Of Life scale (SS-QOL) is a patient-centered outcome measure intended to provide an assessment of health-related quality of life specific to patients with stroke. Patients must respond to each question of the SS-QOL with reference to the past week. It is a self-report scale containing 49 items in 12 domains: Mobility, Energy, Upper extremity function, Work/productivity, Mood, Self-care, Social roles, Family roles, Vision, Language, Thinking, Personality. There are 11 subscales. Items are rated on a 5-point Likert scale with higher scores indicate better functioning. The overall SS-QOL summary score (summation of all items) is presented here. Scores range from 49-245.

Outcome measures

Outcome measures
Measure
Peroneal Nerve Stimulation
n=54 Participants
Odstock Dropped Foot Stimulator
Standard of Care
n=56 Participants
No device or ankle foot orthosis
Stroke-Specific Quality of Life Scale (SS-QOL)
Baseline
179.12 Summary Score
Standard Deviation 35.73
175.30 Summary Score
Standard Deviation 40.67
Stroke-Specific Quality of Life Scale (SS-QOL)
12-weeks
191.62 Summary Score
Standard Deviation 42.39
185.42 Summary Score
Standard Deviation 34.76
Stroke-Specific Quality of Life Scale (SS-QOL)
24-weeks
195.66 Summary Score
Standard Deviation 38.25
184.87 Summary Score
Standard Deviation 38.88
Stroke-Specific Quality of Life Scale (SS-QOL)
36-weeks
190.23 Summary Score
Standard Deviation 44.73
182.95 Summary Score
Standard Deviation 39.76

SECONDARY outcome

Timeframe: baseline, 12, 24 and 36 weeks

Outcome measures

Outcome measures
Measure
Peroneal Nerve Stimulation
n=54 Participants
Odstock Dropped Foot Stimulator
Standard of Care
n=56 Participants
No device or ankle foot orthosis
Gait Speed
Baseline
0.35 meters/sec
Standard Deviation 0.20
0.40 meters/sec
Standard Deviation 0.24
Gait Speed
12-weeks
0.40 meters/sec
Standard Deviation 0.25
0.47 meters/sec
Standard Deviation 0.24
Gait Speed
24-weeks
0.44 meters/sec
Standard Deviation 0.28
0.46 meters/sec
Standard Deviation 0.25
Gait Speed
36-weeks
0.44 meters/sec
Standard Deviation 0.28
0.47 meters/sec
Standard Deviation 0.24

Adverse Events

Peroneal Nerve Stimulation

Serious events: 21 serious events
Other events: 39 other events
Deaths: 0 deaths

Standard of Care

Serious events: 7 serious events
Other events: 20 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Peroneal Nerve Stimulation
n=54 participants at risk
Odstock Dropped Foot Stimulator
Standard of Care
n=56 participants at risk
No device or ankle foot orthosis
Infections and infestations
infection
0.00%
0/54
1.8%
1/56 • Number of events 1
Musculoskeletal and connective tissue disorders
Muskuloskeletal
5.6%
3/54 • Number of events 3
3.6%
2/56 • Number of events 2
Musculoskeletal and connective tissue disorders
Fall
13.0%
7/54 • Number of events 10
3.6%
2/56 • Number of events 2
Nervous system disorders
Neurologic change
13.0%
7/54 • Number of events 8
0.00%
0/56
Cardiac disorders
Cardiac
7.4%
4/54 • Number of events 4
5.4%
3/56 • Number of events 3
Gastrointestinal disorders
Gastrointestinal
1.9%
1/54 • Number of events 1
0.00%
0/56
Psychiatric disorders
Psychiatric
0.00%
0/54
1.8%
1/56 • Number of events 1
Renal and urinary disorders
Urologic
1.9%
1/54 • Number of events 1
0.00%
0/56

Other adverse events

Other adverse events
Measure
Peroneal Nerve Stimulation
n=54 participants at risk
Odstock Dropped Foot Stimulator
Standard of Care
n=56 participants at risk
No device or ankle foot orthosis
Injury, poisoning and procedural complications
Fall
46.3%
25/54 • Number of events 38
26.8%
15/56 • Number of events 24
Endocrine disorders
Endocrine
1.9%
1/54 • Number of events 1
0.00%
0/56
Musculoskeletal and connective tissue disorders
Muskuloskeletal
24.1%
13/54 • Number of events 16
7.1%
4/56 • Number of events 4
Nervous system disorders
Neurologic
3.7%
2/54 • Number of events 3
5.4%
3/56 • Number of events 3
Skin and subcutaneous tissue disorders
Skin
31.5%
17/54 • Number of events 21
7.1%
4/56 • Number of events 9

Additional Information

Lynne Sheffler, MD

Case Western Reserve University/MetroHealth Medcial Center

Phone: 216-957-3570

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place